Short Summary
FaceTec requests the PTAB Director to deny institution of Jumio’s IPR, arguing that the Board misapplied Fintiv factors and that the case duplicates ongoing litigation. The petition highlights ethical violations, overlapping issues, and time‑bar concerns.
Detailed Summary
In a Director Review request, FaceTec, Inc. asks the PTAB to reverse its decision to institute IPR2025-00106 against Jumio Corporation. The patent owner contends that the Board incorrectly treated several Fintiv factors—rewarding Jumio’s prior counsel’s ethical breaches, underestimating the parties’ investments, and overlooking the complete overlap with two parallel district‑court cases—thereby warranting denial of institution under 35 U.S.C. § 314(a). The petition also points to the lack of a stipulation to avoid duplicative litigation, settled expectations from the patent family’s long history, and potential time‑bar issues involving iProov, urging the Director to deny the IPR to prevent unnecessary burden on the Board and the parties.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Jumio Corporation vs FaceTec, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
United Services Automobile AssociationvsAuto Telematics Ltd.
USAA defends the institution of an IPR against Auto Telematics, arguing the patent owner waived procedural arguments and that the ’728 vehicle‑data‑logging patent is obvious over multiple prior‑art references.
Dyson Technology Limited et al.vsOmachron Intellectual Property Inc. et al.
Court decision.
Samsung Electronics Co., Ltd. et al.vsHannibal IP LLC
Samsung and Hannibal IP have filed a joint motion to terminate IPR2025-01190 over U.S. Patent 11,641,661, citing a settlement that resolves all disputes. The Board has not yet issued a final decision, and the parties seek to end the proceeding and keep the agreement confidential.
Merck Sharp & Dohme LLCvsSurrozen Operating, Inc. et al.
Merck has filed a post‑grant review petition challenging U.S. Patent 12,297,278 covering broad tetravalent Wnt‑surrogate antibodies. The petition asserts lack of written description, enablement, indefiniteness, and anticipation by the Garcia publication.
Perfect CorporationvsZugara, Inc.
Perfect Corp. and Zugara, Inc. entered a confidential settlement and jointly moved to terminate the IPR on Zugara’s virtual‑try‑on patent, citing statutory authority and efficiency concerns.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.